KRX Bio Technology Transfer Index

The company is scheduled to present its next-generation REMAP platform technology at the BIO International Convention, which runs from June 22-25, 2026, to seek new technology transfer opportunities, scheduled.

Q1 2026 earnings release on May 18, 2026, with an estimated 5% market impact from R&D and pipeline updates, scheduled.

Announced a technology licensing and co-development agreement with Inovotherapeutics for the drug candidate 'INV-008' on 2026-05-12. The deal is valued at up to KRW 662.5 billion; high importance is estimated due to the significant contract value relative to annual revenue.

Reported Q1 2026 earnings on 2026-05-12 (separate basis): revenue of KRW 335.7 billion (+6.2% YoY) and operating profit of KRW 27.4 billion (-34.7% YoY). The significant drop in operating profit is expected to have a moderate negative impact.

The Korea Pharmaceutical Distribution Association announced on 2026-05-12 its intention to file a formal complaint with the Fair Trade Commission regarding Daewoong's distribution policy. This regulatory risk is estimated to have a moderate impact.

Hanmi Pharm announced a major organizational restructuring to focus on its 2030 mid-to-long-term growth strategy, particularly the obesity treatment pipeline, scheduled. Low impact estimated as organizational changes typically have delayed market effects.

US partner Evommune announced it is considering expanding the clinical indications for APB-R3 (EVO301) beyond atopic dermatitis to include cardiovascular diseases and food allergies, following positive data. This news led to a significant stock price increase.

Announced a strategic partnership with Tionlab Therapeutics on 2026-05-08 to co-develop a once-monthly Semaglutide-based obesity treatment. Entry into the high-growth obesity market is estimated to have a moderate positive impact.

Alteogen Q1 2026 earnings release (Revenue KRW 71.6B, OP KRW 39.3B) on 2026-05-08 expected; neutral impact estimated as YoY decrease is offset by upfront payments from new licensing deals.

ABL Bio announced Q1 2026 earnings, reporting revenue of KRW 13.1 billion (up from KRW 2.2 billion in Q1 2025) and a narrowed operating loss of KRW 17.2 billion. Medium importance estimated due to significant financial improvement.

Yuhan to present positive results from the Phase 1 clinical trial of YH35995 for Gaucher disease at the IWGGD symposium (2026-05-08); importance is Low as Phase 1 results typically have limited immediate market impact, scheduled.

Announced record Q1 2026 results on May 7, 2026, with revenue of KRW 227.9 billion and operating profit of KRW 89.8 billion, a 249.7% increase YoY; the massive profit growth justifies a high market impact expected.

Yuhan announced an API supply contract worth KRW 56 billion with BridgeBio Pharma for a cardiomyopathy treatment (2026-05-07), with the contract period from May 2026 to March 2028; importance is Low as the contract value is small relative to annual revenue, scheduled.